The latest price target for Bone Biologics (NASDAQ:BBLG) was reported by EF Hutton on April 13, 2023. The analyst firm set a price target for $2.25 expecting BBLG to rise to within 12 months (a possible 71.76% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Bone Biologics (NASDAQ:BBLG) was provided by EF Hutton, and Bone Biologics reiterated their buy rating.

There is no last upgrade for Bone Biologics

There is no last downgrade for Bone Biologics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bone Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bone Biologics was filed on April 13, 2023 so you should expect the next rating to be made available sometime around April 13, 2024.

While ratings are subjective and will change, the latest Bone Biologics (BBLG) rating was a reiterated with a price target of $0.00 to $2.25. The current price Bone Biologics (BBLG) is trading at is $1.31, which is within the analyst’s predicted range.